A5091348407- Intracranial Aneurysms: Treatment and Complications
- Traumatic Brain Injury and Neurovascular Disturbances
- Alzheimer's disease research and treatments
- Nicotinic Acetylcholine Receptors Study
- Intracerebral and Subarachnoid Hemorrhage Research
- Vascular Malformations Diagnosis and Treatment
- Mesenchymal stem cell research
- Nerve injury and regeneration
- Neuroinflammation and Neurodegeneration Mechanisms
- Single-cell and spatial transcriptomics
- Immune cells in cancer
- Glioma Diagnosis and Treatment
- Biomedical and Engineering Education
- Neurosurgical Procedures and Complications
- Diversity and Career in Medicine
- Neuroscience and Neuropharmacology Research
- Peripheral Neuropathies and Disorders
- Pharmacogenetics and Drug Metabolism
- Amyotrophic Lateral Sclerosis Research
- Healthcare professionals’ stress and burnout
- Inflammatory Biomarkers in Disease Prognosis
- Cerebrospinal fluid and hydrocephalus
- Neurogenesis and neuroplasticity mechanisms
- Cardiovascular Effects of Exercise
- Memory and Neural Mechanisms
Jacksonville College
2020-2024
Mayo Clinic in Florida
2019-2024
WinnMed
2020-2024
James Cook University Hospital
2020
Park Centre for Mental Health
2018-2019
The University of Queensland
2016-2019
Louisiana State University Health Sciences Center Shreveport
2019
Center for Neurosciences
2019
University College Hospital at Westmoreland Street
2005
University College London
2005
Introduction: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an increasingly recognized form of immune-mediated encephalitis. Here we present a case that represents the shortest hospitalization-to-bortezomib treatment timeline (42 days), and believe this reflected in patient's outcome with complete independence within short timeframe. Case Report: We describe anti-NMDA 18-year-old African American female presenting progressive, medically refractory disease. Despite two rounds...
Objective: To report the preliminary safety, tolerability, and cerebral spinal fluid (CSF) sampling utility of serial injections concentrated intraventricular nicardipine (IVN) in treatment aneurysmal subarachnoid hemorrhage (aSAH). Methods: We clinical, radiographic, laboratory safety tolerability data a retrospective case series from single academic medical center. All patients with aSAH developed vasospasm despite enteral nimodipine received IVN (2.5 mg/mL). CSF injection are defined...
Abstract Cholinergic basal forebrain (cBF)-derived neurotransmission plays a crucial role in regulating neuronal function throughout the cortex, yet mechanisms controlling cholinergic innervation to downstream targets have not been elucidated. Here we report that removing p75 neurotrophin receptor (p75 NTR ) from cBF neurons induces significant impairment fear extinction consolidation. We demonstrate this is achieved through alterations synaptic connectivity and functional activity within...
Degeneration of basal forebrain cholinergic neurons (BFCNs) precedes hippocampal degeneration and pathological amyloid-beta (Aβ) accumulation, underpins the development cognitive dysfunction in sporadic Alzheimer's disease (AD). We hypothesized that BFCNs causes a decrease neurotrophin levels innervated brain areas, which turn promotes Aβ pathology impairment. Here we show lesion septo-hippocampal pre-symptomatic transgenic amyloid AD mouse model (APP/PS1 mice) increases soluble hippocampus,...
Introduction: Severe, often sudden-onset headache is the principal presenting symptoms of aneurysmal subarachnoid hemorrhage (aSAH). We hypothesized that gabapentin would be safe and tolerable for aSAH-induced headaches reduce concurrent opioid use. Methods: performed a single-center, double-blind, randomized, placebo-controlled trial (registered at ClinicalTrials.gov; NCT02330094) from November 24, 2014, to June 2017, where aSAH patients received either dose-escalating or oral placebo, both...
Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative that destroys memory and cognitive function. Aggregates of hyperphosphorylated tau protein are prominent feature in the brain patients with AD, major contributor to neuronal toxicity progression. However, factors initiate toxic cascade results hyperphosphorylation sporadic AD unknown. Here we investigated whether degeneration basal forebrain cholinergic neurons (BFCNs) and/or resultant decrease neurotrophin signaling...
Subarachnoid hemorrhage is a devastating form of stroke with often detrimental outcomes for patients. Here we describe patient subarachnoid treated nimodipine, which resulted in marked bradycardia junctional atrioventricular heart block. Nimodipine metabolized predominantly by the cytochrome P450 3A subfamily, and its use associated adverse events, such as hypotension bradycardia, can be exacerbated advanced age. Our had CYP3A5*3/*3 genotype, possibly predisposing her to poor metabolism this...
Summary Astrocytes are the most common glial cell type in brain, yet, it is unclear how their activation affects transcriptome of neighboring cells. Engineered G protein-coupled receptors (GPCRs) called Designer Receptors Exclusively Activated by Drugs (DREADDs) enable selective specific types, such as astrocytes. Here, we combine astrocytes hippocampus and cortex healthy mice with single-cell RNA sequencing. Our data show that long-term dramatically alters microglia. Genes were...
Abstract Background We conducted a preliminary phase I, dose-escalating, safety, and tolerability trial in the population of patients with acute intracerebral hemorrhage (ICH) by using human allogeneic bone marrow–derived mesenchymal stem/stromal cells. Methods Eligibility criteria included nontraumatic supratentorial hematoma less than 60 mL Glasgow Coma Scale score greater 5. All were monitored neurosciences intensive care unit for safety cell infusion adverse events. also explored use...
Abstract Nimodipine, an L-type cerebroselective calcium channel antagonist, is the only drug approved by US Food and Drug Administration for neuroprotection of patients with aneurysmal subarachnoid hemorrhage (aSAH). Four randomized, placebo-controlled trials nimodipine demonstrated clinical improvement over placebo; however, these occurred before precision medicine pharmacogenomics was readily available. The standard enteral dose recommended after aSAH 60 mg every 4 hours. However, up to...
May 9, 2019April 2019Free AccessThe Gender Gap in Neurology from the American Academy of Work Force Task Report: Implications by 2025 (S50.006)Tasneem F. Hasan, Marion T. Turnbull, Kenneth A. Vatz, Maisha Robinson, Elizabeth Mauricio, and William D. FreemanAuthors Info & AffiliationsApril 2019 issue92 (15_supplement)https://doi.org/10.1212/WNL.92.15_supplement.S50.006 Letters to Editor